You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Monoclonal Antibody Therapeutics for SARS-CoV-2

  • Authors: Michel D. Kazatchkine, MD; Michel Goldman, MD; Michael G. Ison, MD
  • CPD Released: 3/29/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 3/29/2022
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US rheumatologists, clinical immunologists, and infectious disease specialists.

The goal of this activity is to provide an overview of antibody therapeutics for SARS-CoV-2.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Rationale for the development of neutralizing antibody therapeutics for COVID-19
    • Clinical trial data for monoclonal antibodies against SARS-CoV-2


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Michel D. Kazatchkine, MD

    Special Advisor, Joint United Nations Program on AIDS (UNAIDS) in Eastern Europe and Central Asia
    Senior Fellow, Global Health Center,
    The Graduate Institute of International and Development Studies
    Geneva, Switzerland

    Disclosures

    Disclosure: Michel D. Kazatchkine, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ExeVir Bio
    Owns stock, stock options, or bonds from: ExeVir Bio

  • Michel Goldman, MD

    Founder and Co-Director
    I3h Institute
    Université libre de Bruxelles
    Brussels, Belgium

    Disclosures

    Disclosure: Michel Goldman, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: OneLife SA; Vésale Pharma SA
    Other: Michel Consult SPTL

  • Michael G. Ison, MD

    Professor of Medicine
    Division of Infectious Diseases
    Northwestern University Feinberg School of Medicine
    Chicago, Illinois, United States

    Disclosures

    Disclosure: Michael G. Ison, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Adagio; AlloVir; Celltrion Healthcare; Cidara Therapeutics, Inc.; Eurofins Viracor, Inc.; Genentech, Inc./Roche; Janssen Pharmaceuticals, Inc.; Shionogi & Co., Ltd.; Takeda Pharmaceuticals North America, Inc.
    Received grants for clinical research from: AiCuris; Janssen Pharmaceuticals, Inc.; Shire

Editor

  • Gillian Griffith, BA (Mod), MA

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Gillian Griffith, BA (Mod), MA, has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Monoclonal Antibody Therapeutics for SARS-CoV-2

Authors: Michel D. Kazatchkine, MD; Michel Goldman, MD; Michael G. Ison, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 3/29/2021

Valid for credit through: 3/29/2022

processing....

Note: The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication. We continue to add to the collection of activities on this subject as new information becomes available. In order to facilitate disseminating this educational activity as quickly as possible, the associated slides will be included 1 to 2 weeks after the activity posting date.